Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 4/20 | 0.55 |
| ▸ | HTR1B | P28222 | 4/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | HTR1A | P08908 | 2/20 | 0.54 |
| ▸ | HTR2A | P28223 | 1/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.54 |
| ▸ | HTR6 | P50406 | 6/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | IDO1 | P14902 | 2/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31494628 | 1.00 | HTR1D (0.55) | HTR1DHTR1BKMT2AHTR1AHTR2A | |
| SCHEMBL8568165 | 1.00 | HTR1D (0.55) | HTR1DHTR1BKMT2AHTR1AHTR2A | |
| SCHEMBL4788826 | 1.00 | HTR1D (0.55) | HTR1DHTR1BKMT2AHTR1AHTR2A | |
| SCHEMBL1176937 | 0.81 | HTR6 (0.51) | KMT2AHTR6MAPTKDM4EALDH1A1 | |
| SCHEMBL1177303 | 0.81 | HTR6 (0.51) | KMT2AHTR6MAPTKDM4EALDH1A1 | |
| SCHEMBL1177553 | 0.81 | HTR6 (0.51) | KMT2AHTR6MAPTKDM4EALDH1A1 | |
| SCHEMBL837344 | 0.79 | RIPK1 (0.54) | HTR1DHTR1BKMT2AHTR1AHTR2A | |
| SCHEMBL4787924 | 0.79 | HTR1B (0.59) | HTR1DHTR1BKMT2AHTR1AHTR2A | |
| SCHEMBL15220391 | 0.78 | IDO1 (0.54) | KMT2AMAPTKDM4EALDH1A1POLB | |
| SCHEMBL8882446 | 0.77 | ALDH1A1 (0.44) | HTR1DHTR1BKMT2AHTR1AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250059175-A1 | Mutant Pi3k-Alpha Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED | 2025-02-20 | — | — | US | disclosed |
| EP-2582666-B1 | ARYL SUBSTITUTED INDOLES AND THEIR USE AS BLOCKERS OF SODIUM CHANNELS | PURDUE PHARMA LP (US) | 2014-08-13 | — | — | EP | disclosed |
| EP-2582666-A2 | ARYL SUBSTITUTED INDOLES AND THEIR USE AS BLOCKERS OF SODIUM CHANNELS | Purdue Pharma L.P. (US) | 2013-04-24 | — | — | EP | disclosed |
| WO-2011158108-A2 | ARYL SUBSTITUTED INDOLES AND THE USE THEREOF | PURDUE PHARMA L.P. (US) | 2011-12-22 | — | — | WO | disclosed |
| EP-0665846-B1 | TOPOISOMERASE II INHIBITORS AND THERAPEUTIC USES THEREFOR | US HEALTH (US) | 1998-07-29 | — | — | EP | disclosed |
| US-5747520-A | AZATOXIN DERIVATIVES; ANTITUMOR AND ANTICARCINOGENIC AGENTS | US ARMY (US) | 1998-05-05 | — | — | US | disclosed |
| US-5622960-A | ANTICANCER, ANTITUMOR AGENTS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-04-22 | — | — | US | disclosed |
| US-5606060-A | ANTITUMOR AGENTS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 1997-02-25 | — | — | US | disclosed |
| EP-0665846-A1 | TOPOISOMERASE II INHIBITORS AND THERAPEUTIC USES THEREFOR | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1995-08-09 | — | — | EP | disclosed |
| WO-1994010175-A1 | TOPOISOMERASE II INHIBITORS AND THERAPEUTIC USES THEREFOR | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF HEALTH AND HUMAN SERVICES (US) | 1994-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250059175-A1 | Mutant Pi3k-Alpha Inhibitors And Their Use As Pharmaceuticals | PIK3CA, PIK3CD, PIK3R5 | HTR1D 2562/4885HTR1B 2520/4885KMT2A 3767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.